Physicians need clear data to safely prescribe biosimilar medications.
Under many health plans, only the sickest can receive the cure they need.
It’s a small price to pay for patient safety.
Are insurers cost-shifting policies pricing cancer patients out of care?
Lengthy prior authorization processes delay patient access to vital medications.
The difference between a long-shot and a moon-shot.
Without Access, Abuse-Deterrent Pain Medications Can’t Help the Patients Who Need Them